Cardiorenal protection with finerenone is supported by both the ADA and KDIGO guidelines in patients with CKD and T2D.2,3,15 Appropriate patient selection is crucial, with special attention to ensuring that first-line therapies of metformin, SGLT2 inhibitors, maximum tolerated doses of RAS inhibitors (for hypertensive patients), and moderate- or high-intensity statins have been trialed. This evidence concerns the gene SLC5A2 and chronic kidney disease.